Abstract: The invention relates to cosmetic composition comprising a fluorescent-effective amount of at least one fluorescent brightener, in combination with a cosmetically acceptable vehicle. The compositions of the invention can be used as color cosmetics and skin treatment products, to replenish the skin's natural fluorescent glow.

Abstract: Disclosed are cosmetic compositions, including lipsticks, comprising from 0.01% to about 50%, by weight, of cylindrical crystalline vitamin B3 particles having a particle size distribution such that at least about 70% of the crystalline particles have a height to width ratio greater than 1; from about 1% to about 90%, by weight, of an emollient component; from about 1% to about 90%, by weight, of a solidifying agent; and from about 1% to about 90%, on an anhydrous basis, of a color. The compositions provide improved skin feel of crystalline vitamin B3 compounds when applied to skin.

Abstract: Methods and apparatus for improving administration of drugs through the use of heat and other physical means. The present invention relates to the use of heat and other physical means in conjunction with specially designed dermal drug delivery systems, conventional commercial dermal drug delivery systems, or drugs delivered into a sub-skin depot site via injection and other methods to alter, mainly increase, the drug release rate from the dermal drug delivery systems or the depot sites to accommodate certain clinical needs.

Abstract: Methods and apparatus for improving administration of drugs through the use of heat and other physical means. The present invention relates to the use of heat and other physical means in conjunction with specially designed dermal drug delivery systems, conventional commercial dermal drug delivery systems, or drugs delivered into a sub-skin depot site via injection and other methods to alter, mainly increase, the drug release rate from the dermal drug delivery systems or the depot sites to accommodate certain clinical needs.

Abstract: A novel topical anesthetic preparation is characterized by improved transdermal absorption and efficacy. In a preferred embodiment, the topical preparation contains at least one local anesthetic agent and at least two melting point depressing agents. Also provided is a two-phase liquid composition that contains aqueous and oil phases, the oil phase having a relatively high concentration of a local anesthetic agent to enhance transdermal absorption and efficacy when incorporated into a topical anesthetic preparation. A preferred topical anesthetic preparation includes lidocaine or tetracaine, thymol or menthol, and ethyl alcohol or isopropyl alcohol. The preparation is expected to be safe and effective in obtaining transdermal anesthesia on intact skin and mucous membrane of adults, children, infants and newborns.

Abstract: A transdermal drug delivery system which comprises at least one physiologically active agent or prodrug thereof and at least one dermal penetration enhancer; characterized in that the dermal penetration enhancer is a safe skin-tolerant ester sunscreen.

Abstract: A form-fitting cast-on enclosure arrangement has parallel chucking surfaces for the fixing of metallic workpieces with irregular contours to be processed. A process is provided for the manufacturing and separating of the enclosure arrangement. The enclosure arrangement is made of plastic material and consists of several spaced ribs which are connected by webs. The enclosure arrangement has the advantage that workpieces with irregular contours can be enclosed in a cost-effective and fast manner and can be finished or repaired.

Abstract: Cosmetic or pharmaceutical preparations which are distinguished by an effective content of one or more monomeric or homo- or heterodimeric or homo- or heterotrimeric or homo- or heterotetrameric oligopeptides, where these oligopeptides are based on a structure Asn-Ser-Leu-Asp-Phe SEQ ID NO: 1 as homo- or heteromonomer.

Abstract: Composition characterized in that it comprises, as active principle, at least one compound of formula (I): its topically acceptable salts, which R represents the characterizing chain of a saturated or unsaturated, linear or branched fatty acid containing from 3 to 30 carbon atoms, R1 represents the characterizing chain of an amino acid and m is between 1 and 5, and the constituents of at least one extract and/or of at least one tincture from plants of the Nympheacea family. The composition is useful in cosmetics.

Abstract: A synergistic combination of conjugated linoleic acid and fatty acid esters of ascorbic acid is topically applied to treat skin damage, such as contact dermatitis, atopic dermatitis, xerosis, eczema, rosacea, seborrhea, psoriasis, thermal and radiation burns, other types of skin inflammation, and aging. Typical compositions contain from about 1% to about 25% by weight of a CLA preparation containing 9,11-octadecadienoic acid and 10,12-octadecadienoic acid, and from about 0.5% to about 15% by weight of a saturated fatty acid ester of ascorbic acid such as ascorbyl palmitate.

Abstract: A topical flowable personal care product, and more specifically, a shower gel shampoo, body lotion, moisturizing cream, sunscreen, skin toner, or the like, exhibiting a thermochromic color change, preferably at a discrete temperature, preferably at a temperature between about 20° C. (room temperature) and about 37° C. (skin or shower-water temperature). The composition thus changes in response to body heat or the heat of a bath or shower.

Abstract: Methods and apparatus for improving administration of analgesics through the use of heat. The present invention relates to the use of heat in conjunction with specially designed transdermal analgesic delivery systems and conventional commercial transdermal analgesic delivery systems to alter, mainly increase, the analgesic release rate from the transdermal analgesic delivery systems or the depot sites to accommodate certain clinical needs.

Abstract: An improved sunscreen protection and insect repellent combination composition having an SPF factor of about 2 to about 50 and further having an unexpected, unusually long efficacy period when used in rainy conditions or prolonged periods of high humidity, such as in a tropical or sub-tropical rain forests, or the like, and after the wearer has been underwater. The composition forms a stable emulsion lotion that is easy to store. No special precautions are required by the person who applies the lotion. The composition includes a sunscreen agent, an insect repellent, including p-menthane-3,8-diol, an emulsifying agent, and a film former, all in an aqueous solvent. The composition forms a thin film on the skin, but it is non-greasy to the touch. The lotion is easily removed by scrubbing with soap and water.

Abstract: A filled structure includes a fiber reinforced resinous hollow structure having a tensile strength of at least 30,000 psi, and an inside surface forming a boundary which defines a space. A hard core is provided within the space. The hard core has a density of at least 35 pounds per cubic foot and a compressive strength of at least 1500 psi. The hard core is formed from a mixture of particulate cementitious material and liquid. At least one tendon under stress is provided in the hard core. The tendon is constructed and arranged to exert permanent stress on the hard core.

Abstract: A patch for topical application of an anti-acne formulation has in various embodiments a backing film, a release layer and at least one adhesive polymeric matrix layer located between the backing film and the release layer. The anti-acne formulation is uniformly distributed throughout one or more polymeric matrix layers and has an anti-acne effective amount of at least two agents selected from the group consisting of an anti-microbial, an antiseptic, an anti-irritant, a keratolytic agent, a hormone, a hormone agonist and a hormone antagonist.

Abstract: The invention includes an apparatus and method for transdermal delivery of bupropion base. In the method of this invention, patient is administered parenterally a bupropion base in an amount effective to alleviate withdrawal symptoms and to prevent or reduce craving of nicotine in said patient. Alternatively, an effective amount of bupropion base is delivered to alleviate depression in a patient. A transdermal delivery system includes a bupropion base. The bupropion base can be mixed with an acceptable pharmaceutical carrier.

Abstract: The sun protection oil of the invention is prepared with pure virgin olive oil as a basic constituent, in combination with an addition of vitamins E and A, has a U.V protection five (5) and axcept for its sun protection properties it is a skin treatment, as it retards aging of skill cells and maintains the skin youthfull and soft.

Abstract: The present invention relates to compositions and methods for treating cell damage caused by reactive oxygen species in relation to a variety of skin disorders. More specifically, the present invention relates to the treatment skin disorders through the topical delivery of reactive oxygen metabolite production or release inhibiting compounds.

Abstract: A pharmaceutical preparation adhering to the skin, in particular a TTS, for the release of the active substance 17-&bgr;-estradiol, the concentration of the estradiol contained therein in dissolved form being between its saturation concentration in equilibrium with a gas phase of less than 10% relative air humidity and its saturation concentration in equilibrium with a gas phase of more than 90% relative air humidity, in all matrix layers and, if present, also in an adhesive layer, characterized in that the estradiol quantity contained in the preparation amounts to at least three times the saturation solubility measured at 95% relative air humidity, and that the air enclosed in the package is adjusted to a relative air humidity between 5% and below 0.5%.

Abstract: A composition and a dosage form are disclosed comprising oxybutynin alone/or accompanied by another drug indicated for therapy. A method is disclosed for administering oxybutynin alone/or accompanied by a different drug or for administering oxybutynin and a different drug according to a therapeutic program for the management of incontinence alone, and for other therapy.